These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 32460818)

  • 21. Oral versus intravenous empirical antibiotics in children and adolescents with uncomplicated bone and joint infections: a nationwide, randomised, controlled, non-inferiority trial in Denmark.
    Nielsen AB; Holm M; Lindhard MS; Glenthøj JP; Borch L; Hartling U; Schmidt LS; Rytter MJH; Rasmussen AH; Damkjær M; Lemvik G; Petersen JJH; Søndergaard MJ; Thaarup J; Kristensen K; Jensen LH; Hansen LH; Lawaetz MC; Gottliebsen M; Horsager TH; Zaharov T; Hoffmann TU; Nygaard T; Justesen US; Stensballe LG; Vissing NH; Blanche P; Schmiegelow K; Nygaard U
    Lancet Child Adolesc Health; 2024 Sep; 8(9):625-635. PubMed ID: 39025092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial.
    Kaasch AJ; López-Cortés LE; Rodríguez-Baño J; Cisneros JM; Dolores Navarro M; Fätkenheuer G; Jung N; Rieg S; Lepeule R; Coutte L; Bernard L; Lemaignen A; Kösters K; MacKenzie CR; Soriano A; Hagel S; Fantin B; Lafaurie M; Talarmin JP; Dinh A; Guimard T; Boutoille D; Welte T; Reuter S; Kluytmans J; Martin ML; Forestier E; Stocker H; Vitrat V; Tattevin P; Rommerskirchen A; Noret M; Adams A; Kern WV; Hellmich M; Seifert H;
    Lancet Infect Dis; 2024 May; 24(5):523-534. PubMed ID: 38244557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO): study protocol for a randomized controlled trial.
    Kaasch AJ; Fätkenheuer G; Prinz-Langenohl R; Paulus U; Hellmich M; Weiß V; Jung N; Rieg S; Kern WV; Seifert H;
    Trials; 2015 Oct; 16():450. PubMed ID: 26452342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients.
    Hess U; Böhme C; Rey K; Senn HJ
    Support Care Cancer; 1998 Jul; 6(4):402-9. PubMed ID: 9695210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
    Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
    Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral versus intravenous antibiotic treatment for bone and joint infections (OVIVA): study protocol for a randomised controlled trial.
    Li HK; Scarborough M; Zambellas R; Cooper C; Rombach I; Walker AS; Lipsky BA; Briggs A; Seaton A; Atkins B; Woodhouse A; Berendt A; Byren I; Angus B; Pandit H; Stubbs D; McNally M; Thwaites G; Bejon P
    Trials; 2015 Dec; 16():583. PubMed ID: 26690812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients.
    Vidal L; Ben Dor I; Paul M; Eliakim-Raz N; Pokroy E; Soares-Weiser K; Leibovici L
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD003992. PubMed ID: 24105485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients: protocol for a randomised, multicentre, open-label, superiority clinical trial (BEATLE).
    Laporte-Amargos J; Gudiol C; Arnan M; Puerta-Alcalde P; Carmona-Torre F; Huguet M; Albasanz-Puig A; Parody R; Garcia-Vidal C; Del Pozo JL; Batlle M; Tebé C; Rigo-Bonnin R; Muñoz C; Padullés A; Tubau F; Videla S; Sureda A; Carratalà J
    Trials; 2020 May; 21(1):412. PubMed ID: 32423462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial.
    Hill LF; Clements MN; Turner MA; Donà D; Lutsar I; Jacqz-Aigrain E; Heath PT; Roilides E; Rawcliffe L; Alonso-Diaz C; Baraldi E; Dotta A; Ilmoja ML; Mahaveer A; Metsvaht T; Mitsiakos G; Papaevangelou V; Sarafidis K; Walker AS; Sharland M;
    Lancet Child Adolesc Health; 2022 Jan; 6(1):49-59. PubMed ID: 34843669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials.
    Vidal L; Paul M; Ben dor I; Soares-Weiser K; Leibovici L
    J Antimicrob Chemother; 2004 Jul; 54(1):29-37. PubMed ID: 15201227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Piperacillin-tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen).
    Bitterman R; Koppel F; Mussini C; Geffen Y; Chowers M; Rahav G; Nesher L; Ben-Ami R; Turjeman A; Huberman Samuel M; Cheng MP; Lee TC; Leibovici L; Yahav D; Paul M
    BMJ Open; 2021 Feb; 11(2):e040210. PubMed ID: 33558347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immediate oral versus immediate topical versus delayed oral antibiotics for children with acute otitis media with discharge: the REST three-arm non-inferiority electronic platform-supported RCT.
    Hay AD; Moore MV; Taylor J; Turner N; Noble S; Cabral C; Horwood J; Prasad V; Curtis K; Delaney B; Damoiseaux R; Domínguez J; Tapuria A; Harris S; Little P; Lovering A; Morris R; Rowley K; Sadoo A; Schilder A; Venekamp R; Wilkes S; Curcin V
    Health Technol Assess; 2021 Nov; 25(67):1-76. PubMed ID: 34816795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prophylactic antibiotics for the prevention of infection following operative vaginal delivery (ANODE): study protocol for a randomised controlled trial.
    Knight M; Mottram L; Gray S; Partlett C; Juszczak E;
    Trials; 2018 Jul; 19(1):395. PubMed ID: 30041702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.
    Innes H; Lim SL; Hall A; Chan SY; Bhalla N; Marshall E
    Support Care Cancer; 2008 May; 16(5):485-91. PubMed ID: 17899215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amoxicillin duration and dose for community-acquired pneumonia in children: the CAP-IT factorial non-inferiority RCT.
    Barratt S; Bielicki JA; Dunn D; Faust SN; Finn A; Harper L; Jackson P; Lyttle MD; Powell CV; Rogers L; Roland D; Stöhr W; Sturgeon K; Vitale E; Wan M; Gibb DM; Sharland M
    Health Technol Assess; 2021 Nov; 25(60):1-72. PubMed ID: 34738518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimising the antibiotic treatment of uncomplicated acute appendicitis: a protocol for a multicentre randomised clinical trial (APPAC II trial).
    Haijanen J; Sippola S; Grönroos J; Rautio T; Nordström P; Rantanen T; Aarnio M; Ilves I; Hurme S; Marttila H; Virtanen J; Mattila A; Paajanen H; Salminen P;
    BMC Surg; 2018 Dec; 18(1):117. PubMed ID: 30558607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
    Langton Hewer SC; Smyth AR
    Cochrane Database Syst Rev; 2014 Nov; (11):CD004197. PubMed ID: 25383937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis: BLING III.
    Lipman J; Brett SJ; De Waele JJ; Cotta MO; Davis JS; Finfer S; Glass P; Knowles S; McGuinness S; Myburgh J; Paterson DL; Peake S; Rajbhandari D; Rhodes A; Roberts JA; Shirwadkar C; Starr T; Taylor C; Billot L; Dulhunty JM
    Crit Care Resusc; 2019 Mar; 21(1):63-68. PubMed ID: 30857514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.